Seres Therapeutics (MCRB) Tops Q2 EPS by 24c, Revenues Beat
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.24), $0.24 better than the analyst estimate of ($0.48). Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)